This material is intended for UK medical media only. For journalistic assessment and preparation before publication. New findings show that Xultophy® (insulin degludec/liraglutide; IDegLira), the ...

The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an ...

HealthDay News — For patients with uncontrolled type 2 diabetes, a fixed ratio of insulin degludec/liraglutide is noninferior to continued titration of insulin glargine, according to a study published ...

MELBOURNE, Australia — The use of IDegLira, a fixed-ratio combination of the glucagonlike peptide (GLP)-1 receptor agonist liraglutide (Victoza, Novo Nordisk) and insulin degludec (Tresiba, Novo ...

Combined insulin degludec/liraglutide lowers blood glucose and promotes weight loss without causing excess hypoglycemia among adults with type 2 diabetes who are not well-controlled using insulin ...

fingerprick test Greater HbA1c reduction was seen with insulin degludec/liraglutide vs. insulin glargine, meeting the criteria for noninferiority, according to a study published in JAMA. Greater HbA1c ...

Please provide your email address to receive an email when new articles are posted on . The FDA recently extended the regulatory review period for a fixed combination of insulin degludec and ...

Diabetes, particularly type 2 diabetes (T2D), has become an epidemic in the United States, with a significant portion of patients unable to meet recommended glycemic targets. All individuals with type ...

The European Commission approved an expanded use for a fixed combination of insulin degludec and liraglutide for adults with type 2 diabetes and renal impairment, Novo Nordisk announced in a press ...

Two competing insulin / GLP-1 combinations, one from Sanofi and the other from Novo Nordisk, are under review at FDA. Pills that combine metformin with some other class of medication for type 2 ...

COPENHAGEN (Reuters) - Studies showed Novo Nordisk's insulin degludec lowered blood sugar levels with significantly reduced rates of hypoglycaemia when compared with rival Sanofi's Lantus, the Danish ...

The fixed combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since June 2015 also in adults with type 2 diabetes mellitus when oral antidiabetics ...